SAN DIEGO, Feb. 22, 2016 /PRNewswire/ -- Neurelis, Inc., a specialty
pharmaceutical company focused on the treatment of central nervous
system disorders, today announced that it has finalized a Series A
financing round. The investment, led by LYZZ Capital, is intended to
advance the company's lead program, NRL-1 (intranasal diazepam), through
the remaining clinical work in preparation for FDA submission of a New
Drug Application (NDA) in the US. NRL-1 is being developed for
pediatric, adolescent, and adult epilepsy patients who experience Acute
Repetitive or Cluster Seizures.
"This past year has been both productive and exciting for Neurelis, with
the progress on the NRL-1 program and receiving Orphan Drug Designation
for the product," stated Craig C. Chambliss, President and Chief
Executive Officer of Neurelis. "This financing places us significantly
closer to the goal of providing pediatric, adolescent, and adult
epilepsy patients and caregivers with an effective, well-tolerated, and
user-friendly product for the treatment of Acute Repetitive or Cluster
Seizures. There is an incredible need for a convenient product to treat
these seizures where they occur - at home, work, school, or wherever
the need may arise."
About NRL-1
NRL-1 (intranasal diazepam) is a proprietary formulation of diazepam,
delivered via a nasal formulation in a spray, being developed for the
management of pediatric and adult patients who require intermittent use
of diazepam to control bouts of acute repetitive seizure activity, also
known as cluster seizures. NRL-1 has been granted Orphan Drug
Designation by the FDA. In clinical trials, NRL-1 has demonstrated high
bioavailability, low variability from dose to dose, and was
well-tolerated. There are over 2.7 million people with epilepsy in the
United States with approximately 200,000 new patients diagnosed each
year. It is estimated that between 30% and 40% of these patients are
uncontrolled on oral therapy and are at-risk for acute breakthrough
seizures. Studies have shown that prolonged or repetitive seizures can
cause neurological damage and dramatically increase the risk of changes
in neuropsychological function or even death.
About Neurelis
Neurelis, Inc. is a privately-held San Diego-based specialty
pharmaceutical company organized to license, develop, and commercialize
product candidates for epilepsy and the broader central nervous system
(CNS) market. Neurelis leverages expertise in the development and
commercialization of CNS compounds and strong relationships with leading
researchers and clinicians in these markets to advance unique product
candidates to address significant unmet medical needs. For more
information, go to www.neurelis.com.